Board Member
Regina is Senior Vice President and Globaland Head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases. She is responsible for Metabolism, Biopharmaceuticals at AstraZeneca R&D with accountability for global research and early clinical development up to Ph3 in cardiovascular, renal and metabolic diseases. Regina has a broad scientific background in human and animal physiology and received her PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. After her postdoc, Regina was awarded a prestigious grant from the Swedish Natural Research Foundation (NFR) and lead a research group working at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. Regina joined AstraZeneca in 2001 and has held various leadership positions and she has delivered several candidate drugs many of which has progressed into late-stage development.